Poxel - Pharmaceutical Company set-up to find innovative solutions for metabolic diseases management with a primary focus on type 2 diabetes


The International Diabetes Federation estimates that in 2011, 336 million people around the world have diabetes. This total is expected to rise to 552 million in 2030.

The disease impacts industrialized countries most strongly, but changes in lifestyle, including in developing countries, have led to a dramatic increase in obesity worldwide, a significant risk factor for developing Type 2 diabetes.

The worldwide pharmaceutical market for Type 2 diabetes, 60% of which is represented by oral antidiabetics, is expected to nearly double from $26 billion in 2011 to $48.8 billion in 2021.

Sitemap | Legal
© Poxel SA